Spain will be, as announced by Professor Pedro Guillén at the Royal National Academy of Medicine of Spain, the first country in the world to apply a treatment based on partial cellular reprogramming for knee osteoarthritis. The news is important, yes. But it also deserves a calm reading: are we facing a real medical revolution or a promise that is still too early?
Knee osteoarthritis is a disease in which the cartilage of the joint deteriorates, the surrounding joint area becomes inflamed, and the bone beneath the cartilage is altered. All this can cause pain, stiffness, loss of mobility, and difficulty walking, climbing stairs, or getting up from a chair. The problem is enormous. In Spain, data place osteoarthritis as one of the most frequent musculoskeletal diseases, with figures of around 10 million people affected if we add knee, hip, hand, spine, and other locations.
For a long time, cartilage has been spoken of as if it were almost "inert" tissue, but today we know that it is not entirely so: it remodels slowly and, under certain experimental conditions, it can show some capacity for partial regeneration. Partial cellular reprogramming for knee osteoarthritis is an experimental technique that attempts to rejuvenate cartilage cells with the goal of repairing damaged tissue. In other words, it attempts to return to the cell part of its youthful repair capacity.
In this article, we are going to see what partial cellular reprogramming for knee osteoarthritis is, what is actually known in 2026, what is still unknown, and what this news means for a person who already lives with osteoarthritis today.
What is cellular regeneration for osteoarthritis
Cellular reprogramming for osteoarthritis is an experimental strategy that seeks to change the biological state of certain cells so that they function in a younger and more reparative way.
Generally speaking, reprogramming a cell means modifying its "internal program." An adult cell, for example a cartilage cell, has an identity and specific functions. With aging, inflammation, or continued damage, those cells can lose the capacity to keep the tissue healthy. The idea of cellular reprogramming is to intervene in that state so that the cell recovers functions it had before or activates repair mechanisms.
In knee osteoarthritis, the goal would not simply be to calm the pain for a few weeks, but to act on the damaged joint tissue. This includes, above all, the cartilage, but also the inflammatory environment of the joint and, probably, other tissues involved in the disease.
Difference between total and partial reprogramming
Total cellular reprogramming converts an adult cell into an induced pluripotent stem cell, that is, a cell capable of transforming into many different cell types. This field was born from the so-called Yamanaka factors, a discovery that received the Nobel Prize in 2012 and that completely changed modern cell biology.
In short, total reprogramming "rewinds" the cell so much that it brings it close to an embryonic-like state. This is very powerful, but it can be delicate. If a cell completely loses its identity, it can behave in an unpredictable way. That is why one of the great theoretical risks of total reprogramming is the formation of tumors or the appearance of cells that no longer do what they should in that tissue.
Partial cellular reprogramming attempts to reduce that handicap: to rejuvenate the cell without erasing who it is. Instead of taking it to an embryonic state (a very early phase of development in which cells are not yet specialized), some rejuvenation mechanisms are activated in a controlled and transient way. For example, the cell should continue to be a cartilage cell, but with more functional behavior.
In knee osteoarthritis, there is no interest in creating uncontrolled cells, but rather in helping the damaged cartilage recover part of its maintenance and repair capacity.
How it differs from classic stem cell therapies
Partial cellular reprogramming for knee osteoarthritis is not the same as the stem cell injections already offered by some private clinics.
Many current cellular therapies use mesenchymal stem cells. These cells are usually obtained from bone marrow, fat, or other tissues, and are injected into the joint with the intention of reducing inflammation, modulating the joint environment, and promoting some repair. Their main mechanism is not usually to "turn into" new cartilage directly, but to release signals that can influence inflammation and the tissue's response.
Partial reprogramming does not consist only of introducing cells with reparative potential, but of attempting to rejuvenate cells or tissues so that they recover a more youthful function.
A mesenchymal stem cell therapy would be like bringing in an outside team to help with construction work. Partial cellular reprogramming would be more like trying to get the workers already on the construction site to regain strength, coordination, and the ability to repair the building.
Spain, the first country to apply partial reprogramming for knee osteoarthritis
Spain has placed itself at the center of this news due to the announcement by Prof. Pedro Guillén and the CEMTRO Clinic regarding the application of partial cellular reprogramming for knee osteoarthritis.
The announcement was made in April 2026 in the setting of the Royal National Academy of Medicine of Spain. According to the institutional communication, Prof. Pedro Guillén stated that Spain will be the first country to apply a treatment based on the partial reprogramming of human cells to treat knee osteoarthritis. The news has aroused a lot of interest because osteoarthritis is a very frequent disease and because, as of today, the available treatments help control symptoms, improve function, and delay progression, but they do not usually completely regenerate the lost cartilage.
Now, you have to read the fine print carefully. That a country is going to apply a technique for the first time does not mean that this technique is already available to any patient nor that its efficacy has been demonstrated in large clinical trials.
Timelines and what phase the trials are in
In 2026 this project is in a very initial phase and is not yet part of clinical practice in Spain.
According to the information available, the team is likely adjusting aspects such as dosage, number of applications, and method of administration. This suggests a preparation or transition phase toward clinical studies, but it is not equivalent to a standard approved and offered treatment. In other words, in 2026, partial cellular reprogramming for knee osteoarthritis is a promising line of research, not a consolidated therapy.
How this therapy for knee osteoarthritis works
Partial cellular reprogramming for knee osteoarthritis seeks to rejuvenate cells related to cartilage and the joint environment to promote the repair of damaged tissue. The idea would be to activate a cellular rejuvenation program in a controlled manner. That activation must be partial and transient: just enough to improve cellular function, but not so much that the cell loses its identity. In addition to the cartilage, the goal is for them to act on the joint environment.
Difference between reversing early and advanced osteoarthritis
Attempting to reverse early osteoarthritis is not the same as treating advanced osteoarthritis.
In early or moderate osteoarthritis, there is still living cartilage, even if it is deteriorated. There may also be cells capable of responding to regenerative signals. In this context, a therapy that seeks to rejuvenate cartilage cells would make biological sense.
On the other hand, when the osteoarthritis is very advanced and there is practically no cartilage left, this is no longer as viable. If there is significant deformity, disabling pain, severe loss of joint space, or exposed bone, a knee replacement may still be the most logical option. This is because a regenerative therapy needs something to work on, not to reconstruct any joint at any stage.
That is why, if this technique becomes consolidated, it will likely be studied first in people with early or moderate osteoarthritis.
What we know and what we don't know in 2026
In 2026, partial cellular reprogramming for osteoarthritis remains an experimental therapy, but what we do know is interesting. There is a solid scientific basis behind the concept of cellular reprogramming. There are also preclinical results, that is, in the laboratory and in animals, that point to the possibility of regenerating cartilage or improving damaged joint tissues under certain conditions.
In addition, regenerative medicine for osteoarthritis is moving very fast. The US agency ARPA-H has promoted projects focused on regenerating joints damaged by osteoarthritis, including strategies with biomaterials, biological scaffolds, cellular therapies, and cartilage and bone regeneration in animal models. This does not mean that a cure already exists, but it does mean that the field has ceased to be mere speculation.
The first human trials of partial reprogramming approved by the FDA are not for knee osteoarthritis, but for optic neuropathies. The best-known case is ER-100, from Life Biosciences, a cellular rejuvenation therapy based on partial epigenetic reprogramming for optic nerve diseases. This shows that partial reprogramming is entering the human clinical phase, but it does not yet demonstrate that it works in the knee.
Another path being studied is the inhibition of the 15-PGDH enzyme. Research at Stanford has shown that blocking it can promote cartilage regeneration in mice.
| What we know | What we don't know yet |
|---|---|
| Partial reprogramming seeks to rejuvenate cells without completely erasing their identity | If it will be safe in the long term in the human knee |
| Promising results in cartilage and joint tissue regeneration are being seen in animals | How much cartilage could actually be regenerated in people with osteoarthritis |
| There are already human trials of partial reprogramming for other indications, such as optic neuropathies | If results in the eye or other tissues will carry over to joints |
| The Spanish project has been announced for knee osteoarthritis | Which patients will be candidates and with what exact criteria |
| Early osteoarthritis seems the most logical scenario to start with | If it could avoid prostheses in a significant percentage of patients |
| Regenerative medicine for osteoarthritis is advancing with several parallel lines | Cost, access, public coverage, and availability |
Comparison with other regenerative treatments for knee osteoarthritis
Partial cellular reprogramming differs from other regenerative treatments because its goal is not just to calm pain or inflammation, but to try to rejuvenate cells involved in joint damage. There are currently several strategies within regenerative medicine for osteoarthritis. Options such as PRP, mesenchymal stem cells, partial cellular reprogramming, or disease-modifying drugs have different goals and evidence.
| Treatment | Type of intervention | Main goal | Current human evidence | Regulatory situation |
| PRP (Platelet-Rich Plasma) | Injection of the patient's own platelet concentrate | Reduce pain and improve mobility and knee usage capacity | Variable: can help in some mild or moderate cases, but does not demonstrate clear cartilage regeneration | Widespread clinical use, with variable protocols |
| Mesenchymal stem cells | Injection of cells from fat, bone marrow, or other sources | Reduce inflammation, improve pain and function, possible reparative support | Low to moderate according to studies: promising but heterogeneous results | In trials and private medicine, not a universal standard treatment |
| Lorecivivint and other drugs | Drug regulating osteoarthritis biological pathways | Modify disease progression, not just alleviate symptoms | Advanced clinical development; data communicated in trials | In regulatory process in the United States, standard use not generalized |
| 15-PGDH inhibitors | Drug targeting an aging and regeneration pathway | Promote cartilage regeneration | Preclinical evidence in animal models and human ex vivo tissue | Experimental |
| Partial cellular reprogramming | Controlled rejuvenation of cells without erasing their identity | Regeneration and possible reversal in early phases | No published human trials for knee osteoarthritis in 2026 | Experimental |
Who could be an ideal candidate for partial cellular reprogramming in the future?
The ideal candidate for partial cellular reprogramming for knee osteoarthritis will likely be a person with early or moderate osteoarthritis, with enough living cartilage and without advanced joint destruction.
On the other hand, it will likely not be useful or will not be the first option in some cases:
- Very advanced osteoarthritis, with near-complete loss of cartilage
- Knees with severe deformity and irreversible structural damage
- People who already have a prosthesis implanted in the knee
- Patients with serious comorbidities that increase risks or make follow-up difficult
La partial cellular reprogramming for knee osteoarthritis could make more sense when there is still tissue to rescue, not when the joint is already destroyed.
What this means for someone who has osteoarthritis today
This news does not change what your rheumatologist or orthopedic surgeon will recommend to you today, but it does open a door to new options in the coming years.
If you have knee osteoarthritis in 2026, it is normal for news like this to arouse excitement about whether the treatment could be an option. The answer is that we still don't know. But we do know what measures make sense today to take care of the knee and gain quality of life.
- Maintain adapted exercise: Well-guided exercise is one of the most important tools in osteoarthritis. Strengthen muscles, improve stability, and maintain mobility. Walking, adapted strength exercises, gentle stationary bike, water exercises, or physical therapy can help a lot if adjusted to each case.
- Work with physical therapy when there is pain or limitation: A physical therapist can help you improve your strength, balance, mobility, and the way you move. In knee osteoarthritis, small changes in gait, climbing stairs, or quadriceps strength can make a significant difference.
- Manage weight (in case of being overweight): The knee supports the weight of our body. Losing some weight, when indicated, can reduce pain and improve function. It should not be approached as an aesthetic requirement, but rather as a way to unload the joint.
- Use medication or injections (only under medical advice): In certain cases, analgesics, anti-inflammatories, hyaluronic acid, corticosteroids, PRP, or other injections can help. However, it must be highly individualized, because not all treatments work for every knee or have the same evidence base.
- Evaluate supplements with realistic expectations: Some supplements are used for joint health, such as collagen, glucosamine, chondroitin, turmeric, or omega-3. The evidence is not the same for all of them, and the effects, when they appear, are usually modest. They can be a support, but they do not replace exercise, weight management, physical therapy, or medical follow-up.
- Be wary of promises of immediate cures: If a clinic promises to “cure osteoarthritis” with cellular reprogramming outside of a regulated trial, it is best to be cautious. In 2026, this technique remains experimental for knee osteoarthritis. It is sensible to ask for published studies, ethical authorization, trial registration, risks, costs, and inclusion criteria.
